Category Archives: Lymph Node

Organ Systems, Lymph Node, Gastrointestinal, WHO Classification

Enteropathy-Associated T-cell Lymphoma

Immunophenotypic Expression Pattern
Marker
Comment
Positive
Positive
Negative
Negative
Positive
Negative (+ in a subset)
Negative
EBV (EBER)
Negative
Positive
Perforin
Positive
TIA-1
Positive
Variable.  Usually has at least some subset expression (varying intensity).
Negative
Negative
Negative
References
Parker, A., et. al.  “Best Practice in Lymphoma Diagnosis and Reporting.”  British Committee for Standards in Haematology, Royal College of Pathologists.  April, 2010.
 
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.  pp. 289-91.
Organ Systems, Lymph Node, WHO Classification

Extranodal NK/T Cell Lymphoma, Nasal Type

Immunophenotypic Expression Profile
Marker
Comment
Positive
Usually Negative (Surface negative, cytoplasmic epsilon positive)
CD3-ε
Positive (cytoplasmic)
Negative
Negative
Positive
Negative (a few cases are positive)
Positive
Positive
Positive. Not specific for extra nodal NK/T-cell lymphoma, and may be expressed in other T-cell lymphomas.
EBV (EBER)
Positive.  Negative cases should be re-evaluated very closely.
Positive
Perforin
Positive
TIA-1
Positive
Negative
Negative
Negative
References
Parker, A., et. al.  “Best Practice in Lymphoma Diagnosis and Reporting.”  British Committee for Standards in Haematology, Royal College of Pathologists.  April, 2010.
 
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.  pp. 287-88.
Organ Systems, Bone Marrow, Lymph Node, WHO Classification

B-ALL

B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL) accounts for ~80-85% of ALL cases.  75% occur in children < 6 years of age.  The remainder of ALL cases are of T-cell origin.  T-ALL more commonly presents as extra nodal disease.
Immunohistochemical Profile
Stain
Comment
Positive
Positive.  Up to 10% of T-ALL cases may be positive.
Positive in most cases.  CD10 negative cases may be associated with MLL gene rearrangements.
Variably positive.
CD22
Positive (cytoplasmic)
Variably positive.  t(12;21) and hyperploidy cases are often CD34+.
+/-
Positive.  Approximately 95% sensitive.
CD13
+/-  Myeloid markers do not exclude the possibility of an ALL.
+/-  Myeloid markers do not exclude the possibility of an ALL.
MPO
Negative.  Positivity would support either an AML or a B/myeloid leukemia.
Typically Negative
Expression is associated with t(9;22) in adults.
Positive (nuclear expression).  Sensitive and specific marker of B-cell lineage, but a subset of AMLs may express PAX-5 [t(8;21)].
MPO – myeloperoxidase
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
Organ Systems, Lymph Node, WHO Classification

Burkitt Lymphoma

Burkitt lymphoma is a high grade B cell lymphoma composed of medium-sized monomorphic lymphoid cells. The cytology of the nuclei includes finely dispersed chromatin. By touch prep, the cells resemble lymphoblasts, often with cytoplasmic lipid filled vacuoles. In tissue section, the nuclear appearance can be variable from regular round appearance to that with more irregularity. Continue reading Burkitt Lymphoma →

Organ Systems, Lymph Node, WHO Classification

Lymphocyte Depleted Classical Hodgkin Lymphoma (LDCHL)

Less than 1% of cases of classical Hodgkin lymphoma (CHL) fall into this category.  This variant is manifested by numerous Hodgkin’s/ Reed-Sternberg cells without a significant reactive inflammatory infiltrate.  These cases can easily be mistaken for other types of malignancy or anapestic large cell lymphoma.  Immunophenotyping is critical.  EBV infection is present in >90% of cases,  And is more common in HIV-positive individuals, older adults, and third world countries.  Co-expression of CD30 and PAX-5 is helpful to differentiate from a aplastic large cell lymphoma (ALCL).
Classical Hodgkin Lymphoma – General Information
 
Characteristic Immunohistochemical Features
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.
Organ Systems, Lymph Node, WHO Classification

Lymphocyte-Rich Classical Hodgkin Lymphoma (LRCHL)

This is an uncommon classical Hodgkin lymphoma variant (5% of CHL), which is characterized by a predominant reactive lymphocyte infiltrate without significant histiocytes, plasma cells, and eosinophils that are characteristic of the mixed-cellularity variant.  The difficult differential diagnosis is separating this entity from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) as both usually have a nodular pattern.  Prior to good immunohistochemical characterization many cases of lymphocyte-rich and NLPHL were misclassified.  EBV infection is present in approximately 40% of cases.  The immunophenotype of lymphocyte-rich Hodgkin lymphoma is the same is other classical Hodgkin lymphomas.  
 
The immunophenotype combined with identification of Reed-Sternberg cells is the main way to differentiate from nodular lymphocyte predominant Hodgkin lymphoma.  CD21 (follicular dendritic marker) is helpful to highlight the nodules (which contain the neoplastic cells) and small/regressed germinal centers usually at the periphery of the nodules (do not contain the neoplastic cells).  Historically, 30% of cases were misclassified (NLPHL vs. LRCHL), and cannot be reliably differentiated without immunohistochemistry.
Classical Hodgkin Lymphoma – General Information
 
Characteristic Immunohistochemical Features
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.
Organ Systems, Lymph Node, WHO Classification

Mixed-Cellularity Classical Hodgkin Lymphoma

The second most common Hodgkin lymphoma variant (20–25%), which is characterized by a heterogeneous population of inflammatory cells (T cells, eosinophils, histiocytes, and plasma cells) that are admixed with Hodgkin cells.  Fibrosis is not evident, and EBV infection is present in approximately 70-75% of cases.  The immunophenotype is the same as other classical Hodgkin lymphoma cases.  This is the default category when a case cannot be categorized as another subtype.
 
There may be some interstitial fibrosis, but there are no nodules or broad fibrosis and the capsule is not usually thickened. 
Classical Hodgkin Lymphoma – General Information
 
Characteristic Immunohistochemical Features
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.
Organ Systems, Lymph Node, WHO Classification

Nodular Sclerosing Hodgkin Lymphoma

The most common variant of classical Hodgkin’s lymphoma (65–70% of cases), which is characterized by fibrous collagen bands that divide the lymph node into at least one nodule (fibrosis can range from scant to abundant) and neoplastic Hodgkin cells and Reed-Sternberg (HRS) cells with lacunar morphology (formalin fixation artifact with retraction of the cytoplasm).  The lymph node capsule is usually thickened.
 
Syncytial variant – prominent aggregates of neoplastic Hodgkin cells.
 
The immunophenotype of nodular sclerosing variant is shared with the other variants of classical Hodgkin lymphoma (PAX-5+, CD15+, CD30+, and CD45-).  EBV infection is not common in this subtype (10-40%).
Classical Hodgkin Lymphoma – General Information
 
Characteristic Immunohistochemical Features
References
Hematopathology. [edited by] Jaffe, ES. 1st. ed. Elsevier, Inc. © 2011.
 
Robbins and Cotran Pathologic Basis of Disease.  V Kumar, et al. 9th Edition. Elsevier Saunders. 2015.
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008.